Animal models and therapeutic prospects for Charcot-Marie-Tooth disease.

Annals of neurology

Volumn 74, Issue 3, 2013, Pages 391-396

  Bouhy, Delphine ^a   Timmerman, Vincent ^b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODEL; GENETICS; HUMAN; MUTATION; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODELS, ANIMAL; HUMANS; MUTATION;

EID: 84891546678     PISSN: None     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23987     Document Type: Review

References (82)

1. Barisic N, Claeys KG, Sirotkovic-Skerlev M, et al. Charcot-MarieTooth disease: a clinico-genetic confrontation. Ann Hum Genet 2008;72(pt 3):416–441.
2. Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000;123(pt 7):1516–1527.
3. Baets J, Timmerman V. Inherited peripheral neuropathies: a myriad of genes and complex phenotypes. Brain 2011;134(pt 6): 1587–1590.
4. Reilly MM, Murphy SM, Laura M. Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011;16:1–14.
5. Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord 1991;1:19–29.
6. Refshauge KM, Raymond J, Nicholson G, van den Dolder PA. Night splinting does not increase ankle range of motion in people with Charcot-Marie-Tooth disease: a randomised, cross-over trial. Aust J Physiother 2006;52:193–199.
7. Wetmore RS, Drennan JC. Long-term results of triple arthrodesis in Charcot-Marie-Tooth disease. J Bone Joint Surg Am 1989;71: 417–422.
8. Saltzman CL, Fehrle MJ, Cooper RR, et al. Triple arthrodesis: twenty-five and forty-four-year average follow-up of the same patients. J Bone Joint Surg Am 1999;81:1391–1402.
9. Katona I, Wu X, Feely SM, et al. PMP22 expression in dermal nerve myelin from patients with CMT1A. Brain 2009;132(pt 7): 1734–1740.
10. Robaglia-Schlupp A, Pizant J, Norreel JC, et al. PMP22 overexpression causes dysmyelination in mice. Brain 2002;125(pt 10): 2213–2221.
11. Verhamme C, King RH, ten Asbroek AL, et al. Myelin and axon pathology in a long-term study of PMP22-overexpressing mice. J Neuropathol Exp Neurol 2011;70:386–398.
12. Rautenstrauss B, Zechner U, Hameister H, et al. Expression pattern of the peripheral myelin protein 22kDa (PMP22) in neural and non-neural tissue types of adult wildtype and Trembler mice—a comparative study. J Peripher Nerv Syst 1998;3:117–124.
13. Niemann S, Sereda MW, Rossner M, et al. The “CMT rat”: peripheral neuropathy and dysmyelination caused by transgenic overexpression of PMP22. Ann N Y Acad Sci 1999;883:254–261.
14. Suter U, Welcher AA, Ozcelik T, et al. Trembler mouse carries a point mutation in a myelin gene. Nature 1992;356:241–244.
15. Suter U, Moskow JJ, Welcher AA, et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci U S A 1992;89:4382–4386.
16. Madrid RE, Lofgren A, Baets J, Timmerman V. Biopsy in a patient with PMP22 exon 2 mutation recapitulates pathology of TremblerJ mouse. Neuromuscul Disord 2013;23:345–348.
17. Naef R, Suter U. Impaired intracellular trafficking is a common disease mechanism of PMP22 point mutations in peripheral neuropathies. Neurobiol Dis 1999;6:1–14.
18. Colby J, Nicholson R, Dickson KM, et al. PMP22 carrying the trembler or trembler-J mutation is intracellularly retained in myelinating Schwann cells. Neurobiol Dis 2000;7(6 pt B):561–573.
19. Tobler AR, Liu N, Mueller L, Shooter EM. Differential aggregation of the Trembler and Trembler J mutants of peripheral myelin protein 22. Proc Natl Acad Sci U S A 2002;99:483–488.
20. Sereda MW, Meyer zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of CharcotMarie-Tooth disease (CMT-1A). Nat Med 2003;9:1533–1537.
21. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of CharcotMarie-Tooth disease. Nat Med 2004;10:396–401.
22. Fledrich R, Stassart RM, Sereda MW. Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease. Br Med Bull 2012;102: 89–113.
23. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005;65:681–689.
24. Khajavi M, Shiga K, Wiszniewski W, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007;81:438–453.
25. Meyer zu Horste G, Prukop T, Liebetanz D, et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007;61: 61–72.
26. Fairweather N, Bell C, Cochrane S, et al. Mutations in the connexin 32 gene in X-linked dominant Charcot-Marie-Tooth disease (CMTX1). Hum Mol Genet 1994;3:29–34.
27. Hahn AF, Ainsworth PJ, Naus CC, et al. Clinical and pathological observations in men lacking the gap junction protein connexin 32. Muscle Nerve Suppl 2000;9:S39–S48.
28. Dubourg O, Tardieu S, Birouk N, et al. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with Xlinked Charcot-Marie-Tooth disease. Brain 2001;124(pt 10):1958– 1967.
29. Kleopa KA, Scherer SS. Molecular genetics of X-linked CharcotMarie-Tooth disease. Neuromolecular Med 2006;8:107–122.
30. Scherer SS, Xu YT, Messing A, et al. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice. J Neurosci 2005;25:1550–1559.
31. Jeng LJ, Balice-Gordon RJ, Messing A, et al. The effects of a dominant connexin32 mutant in myelinating Schwann cells. Mol Cell Neurosci 2006;32:283–298.
32. Berghoff M, Samsam M, Muller M, et al. Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene. Mol Cell Neurosci 2005;28:118– 127.
33. Groh J, Weis J, Zieger H, et al. Colony-stimulating factor-1 mediates macrophage-related neural damage in a model for CharcotMarie-Tooth disease type 1X. Brain 2012;135(pt 1):88–104.
34. Groh J, Heinl K, Kohl B, et al. Attenuation of MCP-1=CCL2 expression ameliorates neuropathy in a mouse model for CharcotMarie-Tooth 1X. Hum Mol Genet 2010;19:3530–3543.
35. Shy ME. Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci 2006;242:55–66.
36. Warner LE, Hilz MJ, Appel SH, et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron 1996;17:451–460.
37. De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999;122(pt 2):281–290.
38. Inoue K, Khajavi M, Ohyama T, et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet 2004;36:361–369.
39. Khajavi M, Inoue K, Wiszniewski W, et al. Curcumin treatment abrogates endoplasmic reticulum retention and aggregationinduced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet 2005;77:841– 850.
40. Kulkens T, Bolhuis PA, Wolterman RA, et al. Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B. Nat Genet 1993;5:35–39.
41. Wrabetz L, D’Antonio M, Pennuto M, et al. Different intracellular pathomechanisms produce diverse myelin protein zero neuropathies in transgenic mice. J Neurosci 2006;26:2358–2368.
42. Ajroud-Driss S, Deng HX, Siddique T. Recent advances in the genetics of hereditary axonal sensory-motor neuropathies type 2. Curr Neurol Neurosci Rep 2011;11:262–273.
43. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994;13:975–988.
44. d’Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011;17:968–974.
45. Garrido C, Paul C, Seigneuric R, Kampinga HH. The small heat shock proteins family: the long forgotten chaperones. Int J Biochem Cell Biol 2012;44:1588–1592.
46. Boncoraglio A, Minoia M, Carra S. The family of mammalian small heat shock proteins (HSPBs): implications in protein deposit diseases and motor neuropathies. Int J Biochem Cell Biol 2012;44: 1657–1669.
47. Acunzo J, Katsogiannou M, Rocchi P. Small heat shock proteins HSP27 (HspB1), alphaB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int J Biochem Cell Biol 2012;44:1622–1631.
48. Wettstein G, Bellaye PS, Micheau O, Bonniaud P. Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity? Int J Biochem Cell Biol 2012;44:1680–1686.
49. Christians ES, Ishiwata T, Benjamin IJ. Small heat shock proteins in redox metabolism: implications for cardiovascular diseases. Int J Biochem Cell Biol 2012;44:1632–1645.
50. Irobi J, Van Impe K, Seeman P, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet 2004;36:597–601.
51. Evgrafov OV, Mersiyanova I, Irobi J, et al. Mutant small heatshock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 2004;36:602–606.
52. Kolb SJ, Snyder PJ, Poi EJ, et al. Mutant small heat shock protein B3 causes motor neuropathy: utility of a candidate gene approach. Neurology 2010;74:502–506.
53. Mandich, P., Grandis, M., Varese, A., Geroldi, A., Acquaviva, M., Ciotti, P., Gulli, R., Doria-Lamba, L., Fabrizi, G.M., Giribaldi, G., Pizzuti, A., Schenone, A., Bellone, E. Severe neuropathy after diphtheria-tetanus-pertussis vaccination in a child carrying a novel frame-shift mutation in the small heat-shock protein 27 gene, Journal of Child Neurology, Volume 25, Issue 1, January 2010, Pages 107-109 DOI: 10.1177/0883073809334387.
54. Holmgren A, Bouhy D, Timmerman V. Molecular biology of small heat shock proteins associated with peripheral neuropathies. eLS 2012; [doi: 10.1002/9780470015902.a0024294]
55. Capponi S, Geroldi A, Fossa P, et al. HSPB1 and HSPB8 in inherited neuropathies: study of an Italian cohort of dHMN and CMT2 patients. J Peripher Nerv Syst 2011;16:287–294.
56. Houlden H, Laura M, Wavrant-De Vrieze F, et al. Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN=CMT type 2. Neurology 2008;71:1660–1668.
57. Almeida-Souza L, Goethals S, de Winter V, et al. Increased monomerization of mutant HSPB1 leads to protein hyperactivity in Charcot-Marie-Tooth neuropathy. J Biol Chem 2010;285:12778– 12786.
58. Almeida-Souza L, Asselbergh B, d’Ydewalle C, et al. Small heatshock protein HSPB1 mutants stabilize microtubules in CharcotMarie-Tooth neuropathy. J Neurosci 2011;31:15320–15328.
59. Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44:1507–1515.
60. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubulestabilizing agents. J Clin Oncol 2006;24:1633–1642.
61. Almeida-Souza L, Timmerman V, Janssens S. Microtubule dynamics in the peripheral nervous system: a matter of balance. Bioarchitecture 2011;1:267–270.
62. Sofola OA, Jin P, Qin Y, et al. RNA-binding proteins hnRNP A2=B1 and CUGBP1 suppress fragile X CGG premutation repeatinduced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007;55:565–571.
63. Pandey UB, Nichols CD. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev 2011;63:411–436.
64. Storkebaum E, Leitao-Goncalves R, Godenschwege T, et al. Dominant mutations in the tyrosyl-tRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy. Proc Natl Acad Sci U S A 2009;106:11782–11787.
65. Vester A, Velez-Ruiz G, McLaughlin HM, et al. A loss-of-function variant in the human histidyl-tRNA synthetase (HARS) gene is neurotoxic in vivo. Hum Mutat 2013;34:191–199.
66. Freeman MR, Doherty J. Glial cell biology in Drosophila and vertebrates. Trends Neurosci 2006;29:82–90.
67. Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2011;19:1971–1980.
68. Herrmann DN. Experimental therapeutics in hereditary neuropathies: the past, the present, and the future. Neurotherapeutics 2008;5:507–515.
69. Mahammad S, Murthy SN, Didonna A, et al. Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation. J Clin Invest 2013;123:1964–1975.
70. Holmgren A, Bouhy D, De Winter V, et al. Charcot-Marie-Tooth causing HSPB1 mutations increase Cdk5-mediated phosphorylation of neurofilaments. Acta Neuropathol 2013;126:93–108.
71. Fabrizi GM, Cavallaro T, Angiari C, et al. Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton. Brain 2007;130(pt 2): 394–403.
72. de Waegh SM, Lee VM, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 1992;68:451–463.
73. Lee SM, Olzmann JA, Chin LS, Li L. Mutations associated with Charcot-Marie-Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome-autophagy pathways. J Cell Sci 2011;124(pt 19):3319–3331.
74. Kwok AS, Phadwal K, Turner BJ, et al. HspB8 mutation causing hereditary distal motor neuropathy impairs lysosomal delivery of autophagosomes. J Neurochem 2011;119:1155–1161.
75. Durieux AC, Vassilopoulos S, Laine J, et al. A centronuclear myopathy—dynamin 2 mutation impairs autophagy in mice. Traffic 2012;13:869–879.
76. Gentil BJ, Minotti S, Beange M, et al. Normal role of the lowmolecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease. FASEB J 2012;26: 1194–1203.
77. Noack R, Frede S, Albrecht P, et al. Charcot-Marie-Tooth disease CMT4A: GDAP1 increases cellular glutathione and the mitochondrial membrane potential. Hum Mol Genet 2012;21:150–162.
78. Misko A, Jiang S, Wegorzewska I, et al. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro=Milton complex. J Neurosci 2010;30:4232–4240.
79. Pedrola L, Espert A, Wu X, et al. GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum Mol Genet 2005;14: 1087–1094.
80. Pla-Martin D, Rueda CB, Estela A, et al. Silencing of the CharcotMarie-Tooth disease-associated gene GDAP1 induces abnormal mitochondrial distribution and affects Ca homeostasis by reducing store-operated Ca entry. Neurobiol Dis 2013;55:140–151.
81. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219–232.
82. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a).The HMSN Collaborative Research Group. Neuromuscul Disord 1991;1:93–97.